NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down – Time to Sell?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $25.40, but opened at $24.02. NewAmsterdam Pharma shares last traded at $25.3180, with a volume of 638,772 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on NAMS shares. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $52.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, Royal Bank Of Canada decreased their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.73.

NewAmsterdam Pharma Price Performance

The firm has a market cap of $3.00 billion, a P/E ratio of -11.61 and a beta of 0.09. The stock has a 50 day moving average of $29.51 and a 200 day moving average of $31.53.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. On average, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Kooij sold 105,000 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johannes Kastelein sold 125,000 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the sale, the insider owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 270,000 shares of company stock valued at $7,757,450 over the last three months. 12.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. KBC Group NV purchased a new position in NewAmsterdam Pharma during the first quarter valued at $37,000. Navalign LLC purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at $46,000. Finally, Empowered Funds LLC bought a new stake in NewAmsterdam Pharma in the fourth quarter worth $85,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.